Peptide Comparisons
Side-by-side research breakdowns covering mechanisms, receptor targets, clinical data, half-lives, and which compound fits which research protocol. Built for researchers who need the details without the noise.
Weight Loss
The three generations of GLP-1 based weight loss peptides compared — receptor targets, peak weight loss data, FDA status, and mechanisms.
Dual agonist vs triple agonist — what the glucagon receptor adds to tirzepatide's profile and whether Retatrutide's Phase 2 data makes it the new leader.
Amylin analogue vs GLP-1 mono-agonist vs GLP-1/GIP/glucagon triple agonist — why Cagrilintide is usually stacked with a GLP-1 agonist (CagriSema) rather than used alone.
Two dual-receptor GLP-1 peptides, two different second targets — Tirzepatide pairs GLP-1 with GIP, Mazdutide pairs GLP-1 with glucagon (GCGR).
Localized lipolysis injectable vs systemic NNMT inhibitor — targeted spot fat reduction vs whole-body metabolic modulation.
Healing & Recovery
Local vs systemic healing — BPC-157 excels at tendon and gut repair at the injection site; TB-500 acts body-wide for muscle and cardiac recovery.
Acute local repair vs structural regeneration — BPC-157 for tendon, ligament, and gut injury; GHK-Cu for skin, collagen, and long-horizon tissue remodelling.
Same thymic family, different jobs — Thymosin Alpha-1 governs T-cell immune function while TB-500 drives systemic tissue repair.
Buying guide — the pre-blended Recovery Blend for simplicity vs separate BPC-157 and TB-500 vials for independent dosing control.
Performance & GH Axis
Two different receptor pathways — GHSR vs GHRH-R — and why combining them produces synergistic GH output rather than just additive effects.
Pulsatile daily dosing vs once-weekly sustained elevation — the half-life difference between the two CJC-1295 versions changes the entire research protocol.
GH/IGF-1 axis vs mitochondrial AMPK signalling — Tesamorelin for visceral fat and GH research, MOTS-c for metabolic and exercise-capacity research.
Downstream IGF-1 receptor signal vs upstream direct growth hormone replacement — two different points on the same anabolic axis.
Direct exogenous growth hormone vs a dual-pathway GHRH/ghrelin secretagogue blend that stimulates your own pituitary.
Longevity & Metabolic
Three foundational longevity compounds — cellular energy coenzyme vs master antioxidant vs telomerase-activating tetrapeptide.
Two mitochondria-targeted peptides at different levels — cardiolipin structural stabilisation vs AMPK metabolic signalling.
Three exercise mimetics, three mechanisms — AMPK activation, ERR nuclear receptor agonism, and NNMT inhibition compared.
Sexual Health
Selective MC3R/MC4R agonist vs full-spectrum melanocortin agonist — PT-141 targets arousal selectively; Melanotan II adds tanning and appetite effects.
Upstream hormonal HPG-axis stimulation vs central melanocortin arousal signalling — two very different routes to sexual health research.
Cognitive & Brain
BDNF elevation and neuroplasticity vs GABAergic anxiolysis — Semax for cognitive enhancement, Selank for anxiety reduction without sedation.
A broad-spectrum neurotrophic peptide mixture vs a single targeted BDNF-elevating heptapeptide, both with substantial clinical stroke-recovery data.
The bonding hormone vs a benzodiazepine-free anxiolytic — social-bonding-driven anxiolysis vs direct neurochemical modulation.
Skin & Aesthetic
A SNARE-complex expression-line relaxer vs a copper peptide for collagen remodelling — dynamic wrinkles vs structural skin quality.